Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer

Launched by UNIVERSITY OF OKLAHOMA · Jun 9, 2025

Keywords

ClinConnect Summary

The Navigator-Assisted Hypofractionation (NAVAH) clinical trial is looking to understand how well radiation therapy is completed among certain groups of breast and prostate cancer patients. The study focuses on patients from underrepresented backgrounds, specifically those who are African American, Native American, or Hispanic. Researchers want to see how helpful patient navigators—who guide patients through their treatment—can be in making sure patients stick to their radiation therapy plans.

To be eligible for this trial, participants must be 18 years or older and have a confirmed diagnosis of breast or prostate cancer. They also need to agree to participate and provide written consent. The trial is not currently recruiting, but once it starts, participants can expect support from navigators who will help them understand their treatment and ensure they complete their radiation therapy as planned. This study aims to improve care and treatment adherence for these important communities.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects must have histologically or cytologically confirmed Breast or Prostate Cancer.
• • Subjects must be 18 years of age or older. This study requires informed consent by the subject.
• • Subjects must be of African American race, Native American race, or Hispanic ethnicity.
• • Subjects scheduled to undergo RT for Cancer Treatment.
• • Subjects must have the ability to understand and the willingness to sign a written informed consent document.
• Exclusion Criteria:
• • Subjects NOT of African American race, Native American race or Hispanic ethnicity.
• • Subjects WITHOUT histologically/cytologically confirmed Breast or Prostate Cancer.
• • Subjects younger than 18 years old.